None listed
Conditions
Brief summary
The PROSPECT-OA study is a national registry that will track patients with osteoarthritis who receive radiotherapy as part of their standard clinical care. Osteoarthritis is a common condition that causes joint pain and stiffness, and radiotherapy is sometimes used to help manage symptoms. This registry aims to collect real-world information about treatment patterns, pain levels, and patient outcomes across GenesisCare sites in Australia. We hypothesise that radiotherapy can provide meaningful pain relief and improve quality of life for patients with osteoarthritis. By collecting data on pain scores and pain response, the study will help clinicians better understand how radiotherapy is used in practice and its impact on patients over time. Participants will be followed for up to 24 weeks after each course of radiotherapy, with pain response assessed at 12 weekly regular intervals.
Interventions
Osteoarthritis (OA) is a chronic, progressive musculoskeletal condition characterised by degeneration of joint cartilage and underlying bone, leading to pain, stiffness, and reduced mobility. The PROSPECT-OA registry aims to prospectively collect real-world, standard-of-care data on treatment patterns and clinical outcomes in patients diagnosed with osteoarthritis who receive radiotherapy as part of their management.
Participants will be observed from baseline (prior to radiotherapy) and followe
Osteoarthritis (OA) is a chronic, progressive musculoskeletal condition characterised by degeneration of joint cartilage and underlying bone, leading to pain, stiffness, and reduced mobility. The PROSPECT-OA registry aims to prospectively collect real-world, standard-of-care data on treatment patterns and clinical outcomes in patients diagnosed with osteoarthritis who receive radiotherapy as part of their management. Participants will be observed from baseline (prior to radiotherapy) and followed for up to 24 weeks after the completion of each radiotherapy course at scheduled follow-up intervals every 12 weeks which is consistent with standard clinical practice. For patients receiving multiple courses (up to three), the observation timeline will reset after each course. Patients will be asked to verbally rate the following via the clinician asking a question and then the clinician recording the response. It is anticipated this will take less than 5minutes. 1. Pain score (VAS) will be assessed using modified Visual Analogue Scale (VAS) with a verbal response from the patient. Patients will be asked to verbally rate their pain on a scale from 0 (no pain) to 10 (worst imaginable pain), 2. The Von Pannewtiz pain relief score will be assessed with a verbal response from the patient. Patients will be asked to verbally rate their response on scale form grade 1 (Complete response (pain free) to grade 5 (progressive disease, worse pain)
Sponsors
GenesisCare
Eligibility
Sex/Gender
All
Age
50 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Adults (greater than or equal to 50 years) 2. Confirmed diagnosis of Osteoarthritis 3. Patient Planned to be treated with radiotherapy for Osteoarthritis at a participating GenesisCare site as part of standard clinical care 4. Not formally withdrawn from the registry via the opt-out process.
Exclusion criteria
1. Patients may be excluded if missing data at critical time points (ie Baseline and 12-week post Radiotherapy) 2. The patient has explicitly opted out of participation in the registry.
Outcome results
None listed